TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioVersys AG ( (CH:BIOV) ) has issued an announcement.
BioVersys AG announced that its lead asset, BV100, has been selected for a Phase 2b trial conducted by the ADVANCE-ID clinical trial network, supported by a SGD 22 million grant from Wellcome. This trial, which will take place across Southeast Asia, aims to generate additional clinical data to support BV100’s future drug application and compare its efficacy with recently approved drugs. The trial’s expansion to 90 patients and the inclusion of multiple treatment arms will enhance BioVersys’ cash position and extend its financial runway, potentially strengthening its market position in addressing drug-resistant infections.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF62.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG is a clinical-stage biopharmaceutical company focused on developing novel antibacterial products targeting serious infections caused by multidrug-resistant bacteria. The company’s primary product, BV100, is an innovative anti-infective designed to combat hospital infections caused by Acinetobacter baumannii, including carbapenem-resistant strains.
Average Trading Volume: 5,345
Technical Sentiment Signal: Strong Sell
For an in-depth examination of BIOV stock, go to TipRanks’ Overview page.